FreshPatents.com Logo
Enter keywords:  

Track companies' patents here: Public Companies RSS Feeds | RSS Feed Home Page
Popular terms

[SEARCH]

Alzheimer topics
Dysfunction
Schizophrenia
Mitochondria
Mitochondrial
Myasthenia Gravis
Epithelium
Acetylcholine
Extinction
Olfactory Epithelium
Fluorescent Probe
Stokes Shift
Inflammation
Hypertension
Antibodies
Monoclonal

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Alzheimer patents



      
           
This page is updated frequently with new Alzheimer-related patents. Subscribe to the Alzheimer RSS feed to automatically get the update: related Alzheimer RSS feeds.

Subscribe to updates on this page: Alzheimer RSS RSS

Date/App# patent app List of recent Alzheimer-related patents
04/17/14
20140107494
 Cognitive impairment determination apparatus, cognitive impairment determination system and program patent thumbnailnew patent Cognitive impairment determination apparatus, cognitive impairment determination system and program
Cerebral blood flow data during cognitive task execution is measured using a functional near infrared spectroscopy method, then characteristic amount extraction is performed after performing primitive analysis on the measured cerebral blood flow data. Then, by using the extracted characteristic amounts and a pre-built model for employing in determination of cognitive impairment, automatic determination is made into clinical diagnostic groups of normal (nc), mild cognitive impairment (mci) and alzheimer's disease (ad).
04/17/14
20140107174
 3-aminocarbazole compound, pharmaceutical composition containing it and preparation method therefor patent thumbnailnew patent 3-aminocarbazole compound, pharmaceutical composition containing it and preparation method therefor
The present invention relates to novel benzoyl derivatives of 3-aminocarbazole, to a pharmaceutical composition containing them, to a method for preparing them and to the use of such compounds for the production of a drug that is useful in the treatment or prevention of disturbances associated with the production of prostaglandin e2 (pge2), for instance inflammatory processes, pain, fever, tumours, alzheimer's disease and atherosclerosis.. .
04/17/14
20140107164
 Arylvinylazacycloalkane compounds and methods of preparation and use thereof patent thumbnailnew patent Arylvinylazacycloalkane compounds and methods of preparation and use thereof
Novel vinylazacycloalkane compounds of formula (i) are disclosed. The compounds are ligands of various nachrs.
04/17/14
20140107118
 Novel heterocyclic derivatives and their use in the treatment of neurological disorders patent thumbnailnew patent Novel heterocyclic derivatives and their use in the treatment of neurological disorders
In which all of the variables are as defined in the specification, pharmaceutical compositions thereof, combinations thereof, and their use as medicaments, particularly for the treatment of alzheimer's disease or diabetes via inhibition of bace-1 or bace-2.. .
04/17/14
20140107109
 Amino-dihydrothiazine and amino-dioxido dihydrothiazine compounds as beta-secretase antagonists and methods of use patent thumbnailnew patent Amino-dihydrothiazine and amino-dioxido dihydrothiazine compounds as beta-secretase antagonists and methods of use
Wherein variables a4, a5, a6, a8, r1, r2, r3, r7 and n of formula i, independently, are defined herein. The invention also provides pharmaceutical compositions comprising the compounds, and corresponding uses of the compounds and compositions for treatment of disorders and/or conditions related to a-beta plaque formation and deposition, resulting from the biological activity of bace.
04/17/14
20140107037
 Methods of treating alzheimer's disease, huntington's disease, autism, or other disorders patent thumbnailnew patent Methods of treating alzheimer's disease, huntington's disease, autism, or other disorders
The disclosure relates, at least in part, to methods of treating autism in a patient in need thereof by administering an effective amount of a disclosed compound, e.g., a nmda receptor glycine site partial agonist.. .
04/17/14
20140107019
 Engineered polypeptides having enhanced duration of action patent thumbnailnew patent Engineered polypeptides having enhanced duration of action
Compounds are provided having inter alia good duration of action, high potency and/or convenient dosing regimens including oral administration. The compounds are engineered polypeptides which incorporate an albumin binding domain in combination with one or more biologically active polypeptides.
04/17/14
20140105890
 Humanized antibodies specific to the protofibrillar form of the beta-amyloid peptide patent thumbnailnew patent Humanized antibodies specific to the protofibrillar form of the beta-amyloid peptide
The present application relates to humanized antibodies specific to the protofibrillar form of the beta-amyloid peptide, and to the use of said antibodies in the field of alzheimer's disease.. .
04/17/14
20140105877
 Composition for moderating  alcohol metabolism and for reducing the risk of alcohol induced diseases patent thumbnailnew patent Composition for moderating alcohol metabolism and for reducing the risk of alcohol induced diseases
The present invention is directed to a composition of matter, in particular a food composition, dietary or food supplementation, and pharmaceutical composition, respectively. The composition of matter reduces the risk of neuropathy, neurodegenerative diseases including late-onset alzheimer's disease, and cancer, in particular of pancreatic, esophageal, oropharyngolaryngeal, liver, colorectal, lung and/or breast cancer, in particular the drug and/or alcohol induced risk of said diseases.
04/10/14
20140100282
 Intranasal administration of pharmaceutical agents for treatment of neurological diseases patent thumbnailIntranasal administration of pharmaceutical agents for treatment of neurological diseases
Pharmaceutical formulations for treating neurological diseases are described, wherein the formulations comprise a pharmaceutically active agent-transport moiety complex. The formulations are suitable for administration via an intranasal route.
04/10/14
20140100218
Treatment of mild and moderate alzheimer's disease
The present invention relates to methods of treatment using [3-(4-{2-butyl-1-[4-(4-chloro-phenoxy)-phenyl]-1h-imidazol-4-yl}-phenoxy)-propyl]-diethyl amine (“compound i”) or a pharmaceutically acceptable salt thereof. In various embodiments, the methods of treatment include treatment of mild-to-moderate dementia of alzheimer's type, diabetes, insomnia, and other indications.
04/03/14
20140094513
Composition and method for neuroprotection against excitotoxic injury
The present invention discloses the combined treatment of memantine (n-methyl-d-aspartate receptor antagonist) and tea polyphenol (an antioxidant and anti-inflammatory agent) is more effective (synergistic) in neuroprotection than either memantine or tea polyphenol alone in mouse excitotoxic injury. These findings provide useful information about the potential application of memantine and tea polyphenols in preventing or treating clinical excitotoxic injury such as brain trauma, brain ischemia, epilepsy, and alzheimer's disease..
04/03/14
20140094467
Method and composition for modulating canonical wnt pathway using folate and inositol
The canonical wnt signaling pathway is implicated in many disorders including neural tube defects, limb malformations, and heart defects, developmental disorders associated with alcohol exposure (fetal alcohol syndrome) or exposure to bipolar medications (i.e. Lithium), wound healing, and alzheimer's disease.
04/03/14
20140094466
Ssh-2 (slingshot-2) inhibitors and methods for making and using them
In alternative embodiments, the invention provides compositions that inhibit the polypeptide ssh-2, or slingshot-2, a phosphatase enzyme that regulates actin filaments, and methods for making and using them, including methods comprising administering compositions of the invention to regulate or modify actin filament polymerization by inhibiting ssh-2, where in one embodiment compositions of the invention slow or inhibit f-actin depolymerization and severing. In alternative embodiments, compositions and methods of the invention are used to slow or inhibit cell motility and/or internal remodeling.
04/03/14
20140094413
Hepatocyte growth factor (hgf) mimics as therapeutic agents
Small molecule, peptidic hepatocyte growth factors mimics, which act as both mimetics and antagonists, have been generated. These molecules have been shown or predicted to have therapeutic potential for numerous pathologies including dementia, alzheimer's disease, parkinson's disease, amyotrphic lateral sclerosis, and other neurodegenerative diseases, spinal cord injury, traumatic brain injury, diabetes and metabolic syndrome, cancer, and defective wound healing..
04/03/14
20140093595
Composition of extract of emblica officinalis and method of preparing the same
The present disclosure relates to a composition of an extract of fruits of emblica officinalis selected from the group consisting of liquid juice of fruits of emblica officinalis, a powder of an alcoholic extract of fruits of emblica officinalis, a powder of a hydro alcoholic extract of fruits of emblica officinalis, a powder of a water extract of fruits of emblica officinalis, a powder of a juice of fruits of emblica officinalis, a powder of dried fruits of emblica officinalis, a powder of a water extract of dried fruits of emblica officinalis, a powder of a pectinase treated water extract of fruits of emblica officinalis, and combinations thereof; a method of preparing such compositions of extract of fruits of emblica officinalis, more particularly which has application as a nutraceutical or pharmaceutical for increasing hdl-c levels in patients with memory loss and dementia especially in patients with neurodegenerative diseases like alzheimer's disease and for the treatment of memory loss especially in alzheimer's disease.. .
03/27/14
20140088306
Radioactive fluorine-labeled quinoxaline compound
Provided is a compound effective as a diagnostic imaging probe targeting amyloid and an agent for alzheimer's disease diagnosis including the compound.. .
03/27/14
20140088126
Rosuvastatin enantiomer compounds
The invention discloses a method for the treatment of diseases, particularly those diseases characterized by diminished or aberrant cellular function, including aids, cancer, and alzheimer's disease. The method comprises administering a therapeutically effective amount of rosuvastatin enantiomer compounds in their (3r, 5r), (3s, 5r), or (3s, 5s) configurations, or pharmaceutically acceptable salts thereof.
03/27/14
20140088081
Amino-heterocyclic compounds
And pharmaceutically acceptable salts thereof, wherein r1, r2, r3, a, and n are as defined herein. Pharmaceutical compositions containing the compounds of formula i, and uses thereof in treating neurodegenerative and cognitive disorders, such as alzheimer's disease and schizophrenia, are also provided..
03/27/14
20140088000
Leptin rescues neurons from alzheimer's disease related pathways triggered by lipid burden
The described invention relates to compositions and methods for rescuing neurons from alzheimer's disease related pathways triggered by lipid burden or metabolic insult.. .
03/27/14
20140087008
Composition for preventing or treating dementia comprising extracts of monsonia species
The present invention relates to a pharmaceutical composition for preventing and/or treating dementia comprising extracts of monsonia sp.; a food composition for preventing and/or improving dementia comprising extracts of monsonia sp.; and a method of preparing an extract of monsonia sp. With excellent inhibitory effect on the formation of β-amyloid.
03/27/14
20140086945
Albumin-amyloid peptide conjugates and uses thereof
The invention provides conjugates comprising albumin and a peptide derived from the c-terminal region of amyloid beta peptide, as well as uses thereof for the treatment of diseases characterized by the deposition of amyloid proteins and, in particular, for the treatment of alzheimer's disease.. .
03/27/14
20140086937
Immunological control of beta-amyloid levels in vivo
Disclosed herein are compositions and methods useful for controlling β-amyloid levels. In particular, the instant invention relates to an antibody that catalyzes hydrolysis of β-amyloid at a predetermined amide linkage are provided.
03/27/14
20140086910
Methods of treating or preventing alzheimer's disease using indane acetic acid derivatives
The present invention provides indane acetic acid and their derivatives and methods for the treating and/or preventing of alzheimer's diseases.. .
03/27/14
20140086887
Adult stem cell line introduced with hepatocyte growth factor gene and neurogenic transcription factor gene with basic helix-loop-helix motif and uses thereof
The present invention relates to an adult stem cell line introduced with an hgf gene and a neurogenic transcription factor gene of a bhlh family, a preparation method of the adult stem cell line, a composition for the prevention or treatment of neurological diseases comprising the adult stem cell line, and a method for treating neurological diseases comprising the step of administering the composition to a subject having neurological diseases or suspected of having neurological diseases. The adult stem cells according to the present invention, which are introduced with an hgf gene and a neurogenic transcription factor gene of a bhlh family, can be used to overcome chronic impairment caused by cell death following stroke.
03/27/14
20140086836
Method for detection of a neurological disease
The present invention provides methods for predicting whether a subject will develop a disease capable of affecting cognitive function. More specifically, the present invention relates to the predictive detection of neurological diseases in a subject.
03/20/14
20140081025
Heteroaromatic ring derivative
Or a pharmaceutically acceptable salt thereof is based on orexin (ox) receptor antagonist activity, is useful in the treatment and prevention of illnesses including sleep disorder, depression, anxiety disorder, panic disorder, schizophrenia, drug dependency, alzheimer's disease, parkinson's disease, huntington's chorea, eating disorders, pain, gastrointestinal disease, epilepsy, inflammation, immunological disease, endocrinological related disease, and hypertension.. .
03/20/14
20140080916
Isolated compounds from turmeric oil and methods of use
Compounds that are central nervous system drug candidates for the treatment of cognitive decline and, more particularly, alzheimer's disease are provided. Methods for treatment, inhibition, and/or abatement of cognitive decline and/or alzheimer's disease with a compound or pharmaceutically acceptable salt of the invention are also provided.
03/20/14
20140080903
Application of alpha-mangostin in preparation of medicaments for alzheimer's disease
The invention discloses a new use of α-mangostin in medicine, which is application of α-mangostin in preparation of medicaments for alzheimer's disease. Under the new working concentration, α-mangostin showed the capability to inhibit the aggregation and deposition of aβ.
03/20/14
20140080902
B- and y -diketones and y -hydroxyketones as wnt/ b -catenin signaling pathway activators
The present invention discloses β-diketones, γ-diketones or γ-hydroxyketones or analogs thereof, that activate wnt/β-catenin signaling and thus treat or prevent diseases related to signal transduction, such as osteoporosis and osteoarthropathy; osteogenesis imperfecta, bone defects, bone fractures, periodontal disease, otosclerosis, wound healing, craniofacial defects, oncolytic bone disease, traumatic brain injuries related to the differentiation and development of the central nervous system, comprising parkinson's disease, strokes, ischemic cerebral disease, epilepsy, alzheimer's disease, depression, bipolar disorder, schizophrenia; eye diseases such as age related macular degeneration, diabetic macular edema or retinitis pigmentosa and diseases related to differentiation and growth of stem cell, comprising hair loss, hematopoiesis related diseases and tissue regeneration related diseases.. .
03/20/14
20140080860
Novel hybrid cholinesterase inhibitors
The invention relates to novel hybrid cholinesterase inhibitors containing the melatonin or its oxidation products unit and tetrahydroacridine unit linked via a carbamate bond. Due to the high selectivity of action, which is expressed with high ratio of ic50 for acetylcholinesterase inhibition to ic50 for butyrylcholinesterase inhibition ([ic50(ache)]/[ic50(bche)]), the novel compounds may be used in relief and/or treatment of the neurodegenerative diseases, among them the alzheimer's disease..
03/20/14
20140080824
Structure-guided identification of binding interactions of human laminin receptor precursor with laminin and identification of compounds that affect binding
The present invention pertains to compounds which interfere with the binding of laminin to the laminin receptor (lamr). Such compounds are useful for treating diseases such as cancer, alzheimer's disease, and certain viral and bacterial infections..
03/20/14
20140080819
Halogen-alkyl-1,3 oxazines as bace1 and/or bace2 inhibitors
The present invention provides compounds of formula (i) having bace1 and/or bace2 inhibitory activity, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances. The active compounds of the present invention are useful in the therapeutic and/or prophylactic treatment of e.g.
03/20/14
20140080817
Heterocyclic compound and use thereof
Wherein each symbol is as defined in the specification, or a salt thereof, which has an ampa (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) receptor potentiating action. The compound of the present invention is useful as a prophylactic or therapeutic drug for depression, schizophrenia, alzheimer's disease or attention deficit hyperactivity disorder (adhd) and the like..
03/20/14
20140080811
Treatment of alzheimer's disease using compounds that reduce the activity of non-selective ca++ activated atp-sensitive cation channels regulatd by sur1 channels
Nsc antagonists are disclosed as useful in the treatment of dementia, in delaying the onset of dementia, and in the prevention of dementia. Dementia so treated may be, for example, alzheimer's disease (ad).
03/20/14
20140079817
Composition for enhancing memory and mitigating neurodegeneration and method thereof
The present invention provides a composition for enhancing memory and mitigating neurodegeneration comprising an effective amount of a ludwigia octovalvis extract. Also disclosed is a method thereof for enhancing memory and mitigating neurodegeneration comprising administering to a subject in need thereof an effective amount of a ludwigia octovalvis extract.
03/13/14
20140074181
Regulation of amyloid beta molecular composition for the treatment of alzheimer's disease
A method of treating alzheimer's disease (ad) is disclosed. The method comprises electrically stimulating a nerve pathway in a brain region of a subject with at least two high frequency spike bursts of electrical currents, the bursts comprising between 2-20 spikes, wherein a frequency of the spikes in the bursts is between 5-200 msec..
03/13/14
20140073809
Preparation method for rivastigmine, intermediates thereof, and preparation method for said intermediates
The present invention provides the preparation method for (s)-3-(1-(dimethylamino)ethyl)phenyl ethyl(methyl)carbamate (formula x compound), the preparation methods for its intermediates (s)-1-(3-methoxyphenyl)-n,n-dimethyl-n—((s)-1-phenylethyl)ethanaminium (formula vi compound), (s)-1-(3-hydroxyphenyl)-n,n-dimethyl-n—((s)-1-phenylethyl)ethanaminium (formula viii compound) and (s)-1-(3-(ethyl(methyl)carbamoyloxy)phenyl)-n,n-dimethyl-n—((s)-1-phenylethyl)ethanaminium (formula ix compound), as well as the method for using above mentioned formula ix compound to prepare rivastigmine which can be used for the treatment of alzheimer's disease. The preparation method for rivastigmine has a reasonable synthetic design with convenient source of raw materials and high total yield, and the product resulted has high chemical and optical purity, which makes it easy for large-scale.
03/13/14
20140073693
Use of ketone esters for prevention of cns oxygen toxicity
The present invention demonstrates the therapeutic use of ketone esters for seizure disorders, alzheimer's disease and malignant brain cancer, which are associated with metabolic dysregulation. The administration of ketone esters resulted therapeutic ketosis and neuroprotection against seizures resulting from cns oxygen toxicity.
03/13/14
20140073681
Methods of treating alzheimer's disease and pharmaceutical compositions thereof
The present invention describes methods of treating dementia comprising administering an effective daily dose of n-(2-(6-fluoro-1h-indol-3-yl)ethyl-(2,2,3,3-tetrafluoropropoxy)benzylamine to improve or augment the effect of an acetylcholinesterase inhibitor.. .
03/13/14
20140073641
1-heterocyclyl-1,5-dihydro-pyrazolo[3,4-d] pyrimidin-4-one derivatives and their use as pde9a modulators
The invention relates to novel 1,6-disubstituted pyrazolopyrimidinones, wherein i.) the nitrogen atom of the pyrazolo-group that is next to the pyrimidino-group is attached to a non-aromatic, organic heterocycle having at least one ring hetero atom selected from o, n and s and ii.) to the c-atom between the two nitrogen atoms of the pyrimidinone-ring a second substituent is bound via an optionally substituted methylene-bridge. According to one aspect of the invention the new compounds are for the manufacture of medicaments, in particular medicaments for the treatment of conditions concerning deficits in perception, concentration, learning or memory.
03/13/14
20140072982
Specific salivary biomarkers for risk detection, early diagnosis, prognosis and monitoring of alzheimer's and parkinson's diseases
Methods by which specific biomarkers in saliva are used for risk detection, early diagnosis, prognosis and monitoring of alzheimer's and parkinson's diseases.. .
03/13/14
20140072654
Cancer with metabolic therapy and hyperbaric oxygen
The present invention demonstrates the therapeutic use of ketone esters for seizure disorders, alzheimer's disease malignant brain cancer, and other cancers, which are associated with metabolic dysregulation. The administration of a ketogenic diet, such as ketone esters, while concurrently subjecting the patient to a hyperbaric, oxygen-enriched environment resulted in therapeutic ketosis.
03/06/14
20140066613
Uridine diphosphate derivatives, compositions and methods for treating neurodegenerative disorders
This disclosure relates to uridine diphosphate (udp) derivatives, compositions comprising therapeutically effective amounts of those udp derivatives and methods of using those derivatives or compositions in treating disorders that are responsive to ligands, such as agonists, of p2y6 receptor, e.g., neuronal disorders, including neurodegenerative disorders (e.g., alzheimer's disease) and traumatic cns injury, as well as pain.. .
03/06/14
20140066488
Inhibitors of memapsin 2 cleavage for the treatment of alzheimer's disease
Proteases such as memapsin 2 are important enzymes, playing roles in a variety of diseases including alzheimer's disease. The inventors have developed inhibitors of memapsin 2 and methods of use therefore in the treatment of disease..
03/06/14
20140066477
Benzazole derivatives, compositions, and methods of use as beta-secretase inhibitors
The present invention is directed to benzazole compounds that inhibit β-site amyloid precursor protein-cleaving enzyme (bace) and that may be useful in the treatment or prevention of diseases in which bace is involved, such as alzheimer's disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which bace is involved..
03/06/14
20140065138
Anti-n3pglu amyloid beta peptide antibodies and uses thereof
The present invention provides anti-n3pglu aβ antibodies or antigen-binding fragment thereof. In addition, the present invention provides the use of the anti-n3pglu aβ antibodies or antigen-binding fragment thereof for the treatment of alzheimer's disease..
02/27/14
20140058097
Pharmaceutical composition for treating alzheimer's disease
Its pharmaceutically acceptable salt, or a solvate thereof as an active ingredient.. .
02/27/14
20140057984
Methods of treating corticobasal degeneration comprising administering metal chelators to the upper one-third of the nasal cavity
Methods for preconditioning and/or providing neuroprotection to the animal central nervous system against the effects of ischemia, trauma, metal poisoning and neurodegeneration, including the associated cognitive, behavioral and physical impairments. Patients diagnosed with, or at risk for, certain diseases or disorders that are associated with risk for cerebral ischemia may benefit, e.g., those at risk for alzheimer's disease, parkinson's disease, corticobasal degeneration, wilson's disease or stroke or those patients having head or spinal cord injury.
02/27/14
20140057974
Methods for therapy of neurodegenerative disease of the brain
A specific clinical protocol for use toward therapy of defective, diseased and damaged neurons in the mammalian brain, of particular usefulness for treatment of neurodegenerative conditions such as parkinson's disease and alzheimer's disease. The protocol is practiced by delivering a definite concentration of recombinant neurotrophin, such as glial cell-derived neurotrophic factor), into a targeted region of the brain (such as the substantia nigra) using a lentiviral expression vector.
02/27/14
20140057967
Method of screening for chaperonin modulator
The present invention relates to a method of screening for modulator of chaperonin that is involved in protein aggregation inducing neurodegenerative diseases such as alzheimer's disease, parkinson's disease and huntington's disease, use of the chaperonin modulator screened by the method for prevention and treatment of neurodegenerative diseases. According to the present invention, novel negative chaperonin modulator is provided, and chaperonin modulator may be more rapidly and conveniently screened with the negative modulator as a target.
02/27/14
20140057939
5-ht4 receptor agonist compounds for treatment of cognitive disorders
The invention provides methods for the treatment of cognitive disorders utilizing specific 5-ht4 receptor agonist compounds, in particular, methods utilizing these compounds in combination with other agents, specifically acetylcholinesterase inhibitors, for the treatment of alzheimer's disease and other cognitive disorders.. .
02/27/14
20140057900
Pro-neurogenic compounds
Compounds and methods for stimulating neurogenesis (e.g., post-natal neurogenesis, including post-natal hippocampal and hypothalamic neurogenesis) and/or protecting neuronal cell from cell death are disclosed herein. In vivo activity tests suggest that these compounds may have therapeutic benefits in neuropsychiatric and/or neurodegenerative diseases such as schizophrenia, major depression, bipolar disorder, normal aging, epilepsy, traumatic brain injury, post-traumatic stress disorder, parkinson's disease, alzheimer's disease, down syndrome, spinocerebellar ataxia, amyotrophic lateral sclerosis, huntington's disease, stroke, radiation therapy, chronic stress, abuse of a neuro-active drug, retinal degeneration, spinal cord injury, peripheral nerve injury, physiological weight loss associated with various conditions, as well as cognitive decline associated with normal aging, chemotherapy, and the like..
02/27/14
20140057877
Therapeutic polyamine compositions and their synthesis
This invention relates to a process of synthesis and composition of open chain (ring), closed ring, linear branched and or substituted polyamines, polyamine derived tyrosine phosphatase inhibitors and ppar partial agonists/partial antagonists via a series of substitution reactions and optimizing the bioavailability and biological activities of the compounds. Polyamines prevent the toxicity of neurotoxins and diabetogenic toxins including paraquat, methyphenyl pyridine radical, rotenone, diazoxide, streptozotocin and alloxan.
02/27/14
20140057364
Method of diagnosing alzheimers disease using saliva
Provided is a method of diagnosing alzheimer's disease. The method of diagnosing alzheimer's disease includes preparing magnetic particles having primary capture antibodies specifically bonded with beta-amyloid adsorbed thereon, introducing saliva containing beta-amyloid into the magnetic particles to bond the beta-amyloid contained in the saliva with the primary capture antibodies, bonding secondary capture antibodies labeled with fluorescent substances to the magnetic particles bonded with the beta-amyloid to form a complex, disposing the complex in a channel region of an photoelectric conversion device in which photoelectric current is changed according to an amount of incident light, and measuring photoelectric current changed by light excited from the complex to quantify a concentration of the beta-amyloid contained in the saliva..
02/27/14
20140057267
Composition and kit for the diagnosis of mild cognitive impairment, which measure an expression level of lipocalin-2, and method for providing information for the diagnosis of mild cognitive impairment
The present invention relates to a composition for the diagnosis of mild cognitive impairment, which includes a formulation measuring an mrna or protein expression level of lipocalin-2 gene, to a kit for the diagnosis of mild cognitive impairment, and to a method for providing information for the diagnosis of mild cognitive impairment using the same. According to the present invention, by using the agent for measuring an mrna or protein expression level of the lipocalin-2 gene, a patient having mild cognitive impairment can be specifically identified by measuring an expression level of lipocalin-2, which is higher in a group of patients having mild cognitive impairment than in both a normal group and a group of patients having alzheimer's disease.; in particular, it is possible to distinguish between a group of patients having mild cognitive impairment and a group of patients having alzheimer's disease.
02/27/14
20140056901
Anti-tau antibodies and compositions for and methods of making and using in treatment, diagnosis and monitoring of tauopathies
The disclosure provides antibodies that bind the n-terminal region of tau and also bind to pathological tau aggregates, conformational epitopes and peptides mimicking these epitopes (mimotopes). The antibodies may be used to treat tauopathies (e.g.
02/20/14
20140051637
Brain-targeting functional nucleic acid and use thereof
The purpose of the invention is to provide a novel therapeutic agent for alzheimer's disease and use thereof. Provided is a therapeutic agent for alzheimer's disease, which contains a cpg oligodeoxynucleotide structure having a brain migration and improved stability or a salt thereof as an active ingredient..
02/20/14
20140051633
Hepatocyte growth factor mimics as therapeutic agents
Small molecule, peptidic hepatocyte growth factors mimics, which act as both mimetics and antagonists, have been generated. These molecules have been shown or predicted to have therapeutic potential for numerous pathologies including dementia (e.g.
02/20/14
20140050784
Pharmaceutical compositions of memantine
The present invention relates to oral dosage forms comprising memantine or a pharmaceutically acceptable salt thereof, pharmaceutical formulations comprising the oral dosage forms, and methods for treating mild, moderate or severe alzheimer's dementia, or neuropathic pain comprising the oral dosage forms and formulations.. .
02/13/14
20140046067
Pharmacologically active alicyclic n,n'-substituted 3,7-diazabicyclo[3.3.1]nonane derivatives and drugs based thereon
The invention relates to novel alicyclic n,n′-substituted diazabicyclo[3.3.1]nonane derivatives of general formula (i) which act as allosteric ampa receptor modulators, and to drugs based thereon which can be used for treating alzheimer's, parkinson's and other neurodegenerative diseases.. .
02/13/14
20140045858
Compound preparation treating alzheimer's disease and preparation method thereof
A compound drug treating alzheimer's disease, which is a transdermal delivery preparation mainly made by combining huperzine a and tetramethylpyrazine phosphate at a certain ratio. The compound preparation can protect the nervous system in synergy, and therefore can guard against and improve alzheimer's disease from multiple targets..
02/13/14
20140045840
Compounds and methods for kinase modulation, and indications therefor
Compounds and salts thereof, formulations thereof, conjugates thereof, derivatives thereof, forms thereof and uses thereof are described. In certain aspects and embodiments, the described compounds or salts thereof, formulations thereof, conjugates thereof, derivatives thereof, or forms thereof are active on fms protein kinase, or on fms and kit protein kinase, or on fms and flt-3 protein kinase.
02/13/14
20140045828
Amino-oxazines and amino-dihydrothiazine compounds as beta-secretase modulators and methods of use
Wherein a1, a2, a3, a4, a5, a6, r2, r7, x, y and z of formula i are defined herein. The invention also includes use of these compounds in pharmaceutical compositions for treatment, prophylactic or therapeutic, of disorders and conditions related to the activity of beta-secretase protein.
02/13/14
20140045820
2,5,6,7-tetrahydro-[1,4]oxazepin-3-ylamine or 2,3,6,7-tetrahydro-[1,4]oxazepin-5-ylamine compounds
Wherein a, b and r1 to r7 are as described below, or to pharmaceutically acceptable salts thereof. These compounds are bace1 and/or bace2 inhibitors and can be used as medicaments for the therapeutic and/or prophylactic treatment of diseases such as alzheimer's disease, diabetes, particularly type 2 diabetes, and other metabolic disorders..
02/13/14
20140044757
Method for selectively inhibiting acat1 in the treatment of alzheimer's disease
The present invention features methods for stimulating clearance of amyloid beta in microglia, decreasing cognitive decline associated with amyloid pathology, and treating alzheimer's disease by selectively inhibiting the expression or activity of acyl-coa:cholesterol acyltransferase 1, but not acyl-coa:cholesterol acyltransferase 2.. .
02/13/14
20140044743
Method for enhancing immune response with peptide
An object of the present invention is to provide a safe and effective method for enhancing an immune response and a medicament for preventing or treating alzheimer disease comprising amyloid β peptide that induces an enhanced immune response. An amyloid β peptide or a portion thereof with addition or insertion of cysteine and a method for enhancing an immune response using the peptide or a method for enhancing an immune response using the peptide together with an adjuvant.
02/13/14
20140044725
Alzheimer's disease treatment method
The invention relates to antibodies which are used in the preparation of a medicament for the treatment of alzheimer's disease. More specifically, the invention relates to the use of an antibody specifically recognizing any one of the predominant variants of the amyloid beta peptide, aβ40 and aβ42, in the preparation of a medicament that is used to prevent and/or treat alzheimer's disease..
02/13/14
20140044690
High-energy compounds for use in alzheimer's and other neurodegenerative diseases
A method of treating or preventing a neurodegenerative disease includes administering an effective amount of a compound to a subject in need thereof. The compound includes a high-energy compound, such as adenosine triphosphate (atp), guanosine triphosphate (gtp), phosphocreatine (pcr), acetyl coenzyme a (acoa), phosphoenol pyruvate (pep), or a combination thereof..
02/13/14
20140044644
Ankyrin g and modulators thereof for the treatment of neurodegenerative disorders
The present invention generally relates to the technical field of medicine, in particular to the field of neurodegenerative, neurological and protein misfolding disorders such as amyloidosis. By establishing a role of ankg in app processing the method of the present invention provides a new insight into the role of ankg in ad pathology and provides ankg as a target, drug, diagnostic agent and particularly as a vaccine in the treatment and diagnosis of the pathogenesis of alzheimer's disease (ad)..
02/13/14
20140044642
Radiopharmaceutical imaging of neurodegenerative diseases
Methods for simultaneously detecting dementia or cognitive impairment, such as alzheimer's disease (ad), parkinson's disease (pd), lewy body dementia (lbd) and vascular dementia (vad) in a patient using dual or multiple radiopharmaceutical probes are provided herein.. .


Popular terms: [SEARCH]

Alzheimer topics: Dysfunction, Schizophrenia, Mitochondria, Mitochondrial, Myasthenia Gravis, Epithelium, Acetylcholine, Extinction, Olfactory Epithelium, Fluorescent Probe, Stokes Shift, Inflammation, Hypertension, Antibodies, Monoclonal

Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patents related to Alzheimer for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Alzheimer with additional patents listed. Browse our RSS directory or Search for other possible listings.
     SHARE
  
         


FreshNews promo



0.4448

3398

3 - 0 - 74